13F Holdings
中文EN

LIPO LIPELLA PHARMACEUTICALS INC.

Pharmaceutical Preparations · OTC · SEC CIK 1347242 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.4%
TTM net income YoY-25.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,387.9%
Net margin-1,367.4%
FCF margin—
EBITDA margin-1,387.2%

Returns

ROE-361.8%
ROA-236.4%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets36.7%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-24.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$536,357$449,617$184,156$259,347
R&D expense$3.61M$3.04M$2.55M$1.46M
SG&A expense$2.00M$2.16M$226,192$718,384
Operating income-$5.08M-$4.75M-$2.59M-$1.92M
Interest expense—$10,848$9,612$6,834
Pretax income-$5.02M-$4.62M-$2.60M-$1.87M
Net income-$5.02M-$4.62M-$2.60M-$1.87M
EBITDA-$5.08M-$4.74M-$2.59M-$1.92M
EPS (basic)-4.79-6.16-0.64-0.55
EPS (diluted)-4.79-6.16-0.64-0.55
Weighted avg. shares (diluted)1.05M750,3834.06M3.41M
Balance sheet
Cash & equivalents$2.18M$3.29M$5.12M$1.41M
Short-term investments———$300,546
Receivables$84,713$32,286$113,655—
Current assets$2.62M$3.43M$5.80M$1.81M
PP&E, net$9,864$12,750——
Total assets$2.67M$3.58M$5.95M$2.01M
Current liabilities$754,417$385,355$1.18M$340,625
Total liabilities$754,417$432,726$1.27M$589,337
Shareholders' equity$1.92M$3.14M$4.68M$1.42M
Shares outstanding1.21M756,7435.74M3.87M
Cash flow statement
Operating cash flow-$3.95M-$3.15M-$1.83M-$989,271
Capital expenditure—$14,434——
Free cash flow—-$3.16M——
Investing cash flow—-$14,434$300,546-$300,546
Financing cash flow$2.84M$1.34M$5.24M$2.10M
Depreciation & amortization$2,886$1,685$0$0

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.